NCT05637073Withdrawn
Effect of Management of the Endometrioma on Ovarian Reserve
Impact of the Type of Treatment of the Endometrioma on Ovarian Reserve
Source: ClinicalTrials.gov · Last updated 8 Jul 2026
Reason given: After months of attempts, an insurmountable difficulty has arisen in recruiting patients at the main center, in addition to the retirement of the principal investigator.
Brief summary (registry, in English)
Investigators aimed at comparing the impact on ovarian reserve of three usual-care management options of endometrioma, laparoscopic cystectomy (LC), hormonal treatment with daily dienogest (HT), or mere ultrasound control (UC). Ovarian reserve will be measured by the effect on the circulating levels of anti-Mullerian hormone (AMH). Secondary objectives will be effect on pelvic pain, other symptoms, sexual function, quality of life, progression in size of the endometrioma, impact on work productivity and activity impairment, and satisfaction with treatment. Participants will be followed by up to one year.
- Status (registry)
- Withdrawn
- Study type
- Observational
- Enrollment
- 0 (actual)
- First submitted
- 22 Oct 2022
- Start date
- 14 Mar 2023
- Primary completion date
- 2 Jun 2026
- Lead sponsor
- University of Valencia
- Diseases
- Endometriosis
- NCT number
- NCT05637073
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous ovarian surgery;
- Previous pathologies involving the ovary, including other ovarian tumors, polycystic ovaries, or pelvic inflammatory disease;
- Previous diagnosis of cancer treated with chemotherapy or local radiotherapy;
- Unhealthy habits, including smoking, alcohol consumption above social level, or illicit drugs;
- Current or previous use of hormonal contraceptives, Gonadotropin-Releasing Hormone (GnRH) analogues, any drug with a known effect on endometriosis, or any drug under investigation, for what a washing up period of 6 months will be required in all cases.
Other illness
- Diseases affecting the endocrine system, diabetes, thyroid, hyperprolactinemia, or the immune system (lupus, Crohn,…);
Other
- Genesic wish;
- Endometrioma >7 cm;
- Insufficient level of autonomy for unrestrictedly signing informed consent;
Who the study is looking for
- Caucasian premenopausal women between 18-39 years with the diagnosis of endometrioma, one or more, with a diameter of up to 7 cm by endovaginal ultrasound. Body mass index comprised between 17-30 Kg/m2
Age in the registry: 18 years to 39 years · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hosp Clinico Universitario-INCLIVA | Valencia | Spain | Unknown status |
| University Hospital Poznan | Poznan | Poland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.